Bimekizumab shows promise for hidradenitis suppurativa
30 Sep 2021
bởiAudrey Abella
The monoclonal IgG1 antibody bimekizumab, which selectively inhibits both interleukin(IL)-17A and 17F, demonstrated clinically meaningful improvements for moderate-to-severe hidradenitis suppurativa (HS) or acne inversa, a phase II study suggests.
